Rolf Einar Engstad
Directeur/Bestuurslid bij Biotec BetaGlucans AS
Profiel
Rolf Einar Engstad is currently the Director at Biotec BetaGlucans AS.
Previously, he worked as the Chief Scientific Officer at ArcticZymes Technologies ASA. He received his graduate and doctorate degrees from the University of Tromso.
Actieve functies van Rolf Einar Engstad
Bedrijven | Functie | Begin |
---|---|---|
Biotec BetaGlucans AS
Biotec BetaGlucans AS Pharmaceuticals: MajorHealth Technology Part of Lallemand, Inc., Biotec BetaGlucans AS is a Norwegian company that specializes in developing M-Gard®, an immunomodulator that enhances the body's defense mechanisms against pathogens. The company is based in Tromsø, Norway. The technology behind M-Gard® has been successfully developed for alternative indications and applications, including nutraceuticals, wound care, and immunotherapy. The CEO of the company is Jethro Holter. Biotec BetaGlucans was acquired by Danstar Ferment AG from ArcticZymes Technologies ASA on December 31, 2020 for $7.93 million. | Directeur/Bestuurslid | - |
Eerdere bekende functies van Rolf Einar Engstad
Bedrijven | Functie | Einde |
---|---|---|
ARCTICZYMES TECHNOLOGIES ASA | Hoofd Techniek/Wetenschap/O&O | - |
Opleiding van Rolf Einar Engstad
University of Tromso | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 1 |
---|---|
ARCTICZYMES TECHNOLOGIES ASA | Health Technology |
Bedrijven in privébezit | 1 |
---|---|
Biotec BetaGlucans AS
Biotec BetaGlucans AS Pharmaceuticals: MajorHealth Technology Part of Lallemand, Inc., Biotec BetaGlucans AS is a Norwegian company that specializes in developing M-Gard®, an immunomodulator that enhances the body's defense mechanisms against pathogens. The company is based in Tromsø, Norway. The technology behind M-Gard® has been successfully developed for alternative indications and applications, including nutraceuticals, wound care, and immunotherapy. The CEO of the company is Jethro Holter. Biotec BetaGlucans was acquired by Danstar Ferment AG from ArcticZymes Technologies ASA on December 31, 2020 for $7.93 million. | Health Technology |